Scholars Central

Conference abstractPublished 26 Oct 2016

An online survey of neurologists about Charcot-Marie-Tooth disease type 1A

Authors: Xavier Paoli

Pharnext, France

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Charcot-Marie-Tooth (CMT) disease is the most common inherited disorder of the peripheral nervous system. CMT type 1A (CMT1A) is an autosomal dominant and demyelinating subtype of CMT, classified as an orphan disease with around 125000 patients across Europe and the US. Presently uncurable, CMT1A significantly impairs quality of life of affected patients. Our survey aimed at understanding the CMT1A patient journey across the US and European healthcare systems and identifying potential barriers that could be alleviated. In October 2014, an online questionnaire was administered to 128 European and US neurologists. Altogether, respondents followed a pool of over 2000 CMT1A patients and had mainly hospital-based activities. Neurologists declared that adult patients usually seek medical care due to symptoms alone contrary to children where family history seems to be more decisive. For most patients, general practitioners, pediatricians and neurologists are the first physicians visited before reaching CMT experts. Physicians use clinical symptomatology, electrophysiology and genetic testing as primary diagnosis tools. Nearly 70% of patients seem to get diagnosed within two years after first symptoms and before the age of 30. Most neurologists surveyed use primarily clinical evaluation of symptoms to gauge disease severity. More than 80% of their patients suffer from mild to moderate CMT1A. Physical therapy, orthotics and pharmacotherapy for neuropathic pain are the most frequent supportive cares. This survey offers a better understanding of the current CMT1A patient journey where the flow could be improved through disease awareness programs developed and led by both neurologists and patient organizations.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Genetic Syndromes & Gene Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Xavier Paoli”